With Wegovy supply unfettered, Novo Nordisk ratchets up its 2023 growth forecast

After working through a supply disruption early in Wegovy’s launch, Novo Nordisk is ready to ride its obesity star’s momentum.

Novo has nearly doubled its growth expectations for the full year after turning in a strong first quarter. The company boosted its sales growth expectations for 2023 to a range of 24% to 30%, up from a prior range of 13% to 19%.